Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s investigational candidate ODM-208 and other drugs that target cytochrome P450 11A1 (CYP11A1). ODM-208, which is an oral, non-steroidal inhibitor of CYP11A1, is presently being assessed by the Finnish pharma company in a phase 2 clinical trial for […]
UK-based liquid biopsy company ANGLE plc has won a pharma services contract worth up to $1.2 million from an undisclosed pharma company that is engaged in developing cancer drugs. The pharma company has chosen ANGLE’s Parsortix system to carry out longitudinal monitoring of patients in three separate clinical trials in prostate cancer and other locally […]
Cancer Targeted Technology (CTT), a Seattle-based biotech company, has secured a grant of $1.44 million from the US National Institutes of Health (NIH) to support an ongoing clinical trial of a new radiotherapeutic called CTT1403 in prostate cancer. According to the company, the NIH grant has been awarded on the second year of a competitive […]
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This strategic acquisition, which was first announced in December 2018, is expected to significantly bolster GSK’s presence in the oncology sector, reinforcing its pharmaceutical business and enhancing its pipeline and commercial […]
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for cancer treatment. The deal, first announced in October 2018, was finalised following shareholder approval earlier this week. A strategic move into radioligand and CAR-T therapies Endocyte specialises in developing radioligand […]
Novartis acquisition of Endocyte : US biopharma company Endocyte has agreed to be acquired by Swiss pharma company Novartis in a deal worth around $2.1 billion. As per the latest pharma acquisition news, Novartis has gone ahead with the deal to enlarge its expertise in radiopharmaceuticals for treating various types of cancers. Novartis Acquisition of […]
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s capabilities in radiopharmaceuticals, particularly for cancer treatment. The acquisition will see Novartis purchase all outstanding shares of Endocyte at $24 per share. Expanding Expertise in Radiopharmaceuticals Endocyte specializes in developing […]
In a significant development, Astellas Pharma and Pfizer have announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of their cancer drug Xtandi (enzalutamide) for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC). This marks an important step forward in the treatment options available to patients suffering from this […]